Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry

Journal of Clinical Oncology

Volumn 18, Issue 21, 2000, Pages 3651-3664

  Pauletti, Giovanni ^a   Dandekar, Suganda ^a   Rong, HongMei ^a   Ramos, Lilllian ^a   Peng, HongJun ^a   Seshadri, Ram ^a   Slamon, Dennis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; ONCOPROTEIN; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER STAGING; DIAGNOSTIC ACCURACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE ISOLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; TISSUE FIXATION;

EID: 0034327895     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.21.3651     Document Type: Article

References (43)

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
3. ERBB 2 amplification in breast cancer analysed by fluorescence in situ hybridization
4. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
5. The HER-2/neu proto-oncogene in human breast cancer
6. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in the immunohistochemical studies of oncogene expression
7. c-erbB- 2 protein overexpression in breast cancer is risk factor in patients with involved and uninvolved lymph nodes
8. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer
9. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
10. HER-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease
11. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
12. The HER-2/neu oncogene: Prognostic factor, predictive factor and target for therapy
13. c-erbB-2 expression and response to adjuvant therapy in women with node- positive early breast cancer
14. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
15. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational controlled phase III trial
16. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
17. Molecular cytogenetics in human cancer diagnosis
18. Optimization of immunohistochemical detection of erbB2 in human breast cancer: Impact of fixation
19. Interphase cytogenetics of the HER-2/neu oncogene in breast cancer
20. Characterization of recurrent homogeneously staining regions in 72 breast carcinomas
21. Relationship between ploidy and steroid hormone receptors in primary invasive breast cancer
22. Relationship between p 53 gene abnormalities and other tumour characteristics in breastcancer prognosis
23. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
24. Differential responses of human tumor cell lines to anti-p 185HER2 monoclonal antibodies
25. erbB-2 (HER-2/neu) gene copy number, p185(HER-2) overexpression and intratumor heterogeneity in human breast cancer
26. Regression models and life tables
27. Correlation of c-erbB- 2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
28. Amplification of the c-erb B- 2 oncogene and prognosis of breast adenocarcinoma
29. ERBB 2 amplification in breast cancer with a high rate of proliferation
30. Prognostic and predictive factors in breast cancer by immunohistochemical analysis
31. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization
32. Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer
33. Association of focal adhesion kinase with Grb 7 and its role in cell migration
34. Identification of Tek/Tie2 binding partners: Binding to a multifunctional docking site mediates cell survival and migration
35. Grb 7 signal transduction protein mediates metastatic progression of esophageal carcinoma
36. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER 2 in breast cancer
37. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu overexpressing invasive human breast tumours
38. NH2-terminally truncated HER-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer
39. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
40. Increased HER2 with U.S. Food and Drug Administration-approved antibody
41. Immunohistochemistry assays for HER2 overexpression
42. Specificity of Hercept-Test in determining HER-2/neu status of breast cancer using the United States Food and Drug Administration-approved scoring system